5122 Journal of Medicinal Chemistry, 2005, Vol. 48, No. 16
Yang et al.
(25) Quan, W. D., Jr.; Dean, G. E.; Spears, L.; Spears, C. P.; Groshen,
S.; et al. Active specific immunotherapy of metastatic melanoma
with an antiidiotype vaccine: a phase I/II trial of I-Mel-2 plus
SAF-m. J. Clin. Oncol. 1997, 15, 2103-2110.
(26) Amiel, C.; De La Tribonniere, X.; Vidal, V.; Darcissac, E.;
Mouton, Y. Clinical tolerance and immunologic effects after
single or repeated administrations of the synthetic immuno-
modulator murabutide in HIV-1-infected patients. J. Acquired
Immune Defic. Syndr. 2002, 30, 294-305.
(27) Killion, J. J.; Fildler, I. J. Therapy of cancer metastasis by
tumoricidal activation of tissue macrophages using liposome-
encapsulated immunomodulators. Pharmacol. Ther. 1998, 78,
141-154.
(28) Fidler, I. J.; Kleinerman, E. S. Therapy of cancer metastasis by
systemic activation of macrophages: from the bench to the clinic.
Res. Immunol. 1993, 144, 284-297.
(29) Darcissac, E. C.; Vidal, V.; Guillaume, M.; Thebault, J. J.; Bahr,
G. M. Clinical tolerance and profile of cytokine induction in
healthy volunteers following the simultaneous administration
of IFN-alpha and the synthetic immunomodulator murabutide.
J. Interferon Cytokine Res. 2001, 21, 655-661.
(30) MacEwen, E. G. E. G.; Kurzman, I. D.; Vail, D. M.; Dubielzig,
R. R.; Everlith, K.; et al. Adjuvant therapy for melanoma in
dogs: results of randomized clinical trials using surgery, lipo-
some-encapsulated muramyl tripeptide, and granulocyte mac-
rophage colony-stimulating factor. Clin. Cancer Res. 1999, 5,
4249-4258.
(31) Zhang, S. D.; Liu, G.; Xia, S. Q.; Wu, P. Design and synthesis of
muramyl dipeptide cyclic analogue. Chin. Chem. Lett. 2002, 13,
17-18.
(32) Zhang, S. D.; Liu, G.; Xia, S. Q. Design and solid-phase synthesis
of multiple muramyl dipeptide (MMD). Chin. Chem. Lett. 2001,
12, 887-888.
(33) Liu, G.; Zhang, S. D.; Xia, S. Q.; Ding, Z. K. Solid-phase synthesis
of muramyl dipeptide (MDP) derivatives using a multipin
method. Bioorg. Med. Chem. Lett. 2000, 10, 1361-1363.
(34) Zhang, S. D.; Liu, G.; Xia, S. Q.; Wu, P.; Zhang, L. “Meshed-Bag
Gathered-Bunch” method for solid-phase synthesis of small
molecular diverse compounds. J. Comb. Chem. 2002, 4, 131-
137.
(35) Gross, P. H.; Rimpler, M. Sterochemically pure derivatives of
muramic and isomuramic acids. Liebigs Ann. Chem. 1986, 37-
45.
(36) Baschang, G. Muramylpeptides and lipopeptides: studies to-
wards immunostimulants. Tetrahedron 1989, 45, 6331-6360.
(37) Gang, L.; Kit, S. L. One-bead one-compound combinatorial
library method. In Combinatorial Chemistry: A Practice Protocol
Approach; Fenniri, H., Ed.; Oxford University Press: Oxford,
2000; pp 33-50.
(38) Cao, X. T.; He, L.; Xia, Z. F.; Ma, S. H.; et al. Lymphotactin gene-
modified bone marrow dendritic cells act as more potent
adjuvants for peptide delivery to induce specific antitumor
immunity. J. Immunol. 1998, 161, 6238-6244.
(39) Chun, E.; Lee, J.; Cheong, H. S.; Lee, K. Y. Tumor eradication
by hepatitis B virus X antigen-specific CD8+ T cells in xe-
nografted nude mice. J. Immunol. 2003, 170, 1183-1190.
(40) Tomohiko, O.; Yasuo, S.; Wataru, K.; Tomoko, H.; Takashi, S.;
Shoichi, K.; et al. Immunobiological activities of chemically
defined lipid A from Helicobacter pylori LPS in comparison with
Porphyromonas gingivalis lipid A and Escherichia coli-type
synthetic lipid A (compound 506). Vaccine 1997, 15, 1598-1605.
(41) Vidal, V.; Dewulf, J.; Bahr, G. M. Enhanced maturation and
functional capacity of monocyte-derived immature dendritic cells
by the synthetic immunomodulator murabutide. Immunology
2001, 103, 479-487.
(42) Gursel, M.; Verthelyi, D.; Klinman, D. M. CpG oligodeoxy-
nucleotides induce human monocytes to mature into functional
dendritic cells. Eur. J. Immunol. 2002, 32, 2617-2622.
(43) Kisseleva, E.; Becker, M.; Lemm, M.; Fichtner, I. Early mac-
rophage and cytokine response during the growth of immuno-
genic and non-immunogenic murine tumors. Anticancer Res.
2001, 21, 3477-3484.
(44) Cappello, P.; Caorsi, C.; Bosticardo, M.; De Angelis, S.; Novelli,
F.; et al. CCL16/LEC powerfully triggers effector and antigen-
presenting functions of macrophages and enhances T cell cyto-
toxicity. J. Leukocyte Biol. 2004, 75, 135-142.
(45) Belyakov, I. M.; Derby, M. A.; Ahlers, J. D.; Kelsall, B. L.; Earl,
P.; et al. Mucosal immunization with HIV-1 peptide vaccine
induces mucosal and systemic cytotoxic T lymphocytes and
protective immunity in mice against intrarectal recombinant
HIV-vaccinia challenge. Proc. Natl. Acad. Sci. U.S.A. 1998, 95,
1709-1714.
(46) Jang, M. H.; Kweon, M. N.; Hiroi, T.; Yamamoto, M.; Takahashi,
I.; Kiyono, H. Induction of cytotoxic T lymphocyte responses by
cholera toxin-treated bone marrow-derived dendritic cells. Vac-
cine 2003, 21, 1613-1619.
(47) Decker, T.; Stockinger, S.; Karaghiosoff, M.; Muller, M.; Kovarik,
P. IFNs and STATs in innate immunity to microorganisms. J.
Clin. Invest. 2002, 109, 1271-1277.
(48) Chambers, C. A.; Allison, J. P. Co-stimulation in T cell responses.
Curr. Opin. Immunol. 1997, 9, 396-404.
(49) Bubenik, J. Genetically engineered dendritic cell-based cancer
vaccines (review). Int. J. Oncol. 2001, 18, 475-478.
(50) Hauben, E.; Gothilf, A.; Cohen, A.; Butovsky, O.; Nevo, U.; et
al. Vaccination with dendritic cells pulsed with peptides of
myelin basic protein promotes functional recovery from spinal
cord injury. J. Neurosci. 2003, 23, 8808-8819.
(51) Gallucci, S.; Lolkema, M.; Matzinger, P. Natural adjuvants:
endogenous activators of dendritic cells. Nat. Med. 1999, 5,
1249-1255.
(52) Steinman, R. M. The dendritic cell system and its role in
immunogenicity. Annu. Rev. Immunol. 1991, 9, 271-296.
(53) Steinman, R. M.; Witmer, M. D. Lymphoid dendritic cells are
potent stimulators of the primary mixed leukocyte reaction in
mice. Proc. Natl. Acad. Sci. U.S.A. 1978, 75, 5132-5136.
(54) Inaba, K.; Steinman, R. M. Accessory cell-T lymphocyte interac-
tions. Antigen-dependent and -independent clustering. J. Exp.
Med. 1986, 163, 247-261.
(55) Lipscomb, M. F.; Masten, B. J. Dendritic cells: immune regula-
tors in health and disease. Physiol. Rev. 2002, 82, 97-130.
(56) Iezzi, G.; Karjalainen, K.; Lanzavecchia, A. The duration of
antigenic stimulation determines the fate of naive and effector
T cells. Immunity 1998, 8, 89-95.
(57) Lanzavecchia, A.; Sallusto, F. Dynamics of T lymphocyte re-
sponses: intermediates, effectors, and memory cells. Science
2000, 290, 92-97.
(58) VanParijs, L.; Refaeli, Y.; Lord, J. D.; Nelson, B. H.; Abbas, A.
K.; et al. Uncoupling IL-2 signals that regulate T cell prolifera-
tion, survival, and Fas-mediated activation-induced cell death.
Immunity 1999, 11, 281-288.
(59) Granucci, F.; Feau, S.; Angeli, V.; Trottein, F.; Ricciardi-
Castagnoli, P. Early IL-2 production by mouse dendritic cells is
the result of microbial-induced priming. J. Immunol. 2003, 170,
5075-5081.
(60) Scott, P.; Trinchieri, G. The role of natural killer cells in host-
parasite interactions. Curr. Opin. Immunol. 1995, 7, 34-40.
(61) Manetti, R.; Gerosa, F.; Giudizi, M. G.; Biagiotti, R.; Parronchi,
P.; et al. Interleukin 12 induces stable priming for interferon
gamma (IFN-gamma) production during differentiation of hu-
man T helper (Th) cells and transient IFN-gamma production
in established Th2 cell clones. J. Exp. Med. 1994, 179, 1273-
1282.
(62) Biron, C. A.; Gazzinelli, R. T. Effects of IL-12 on immune
responses to microbial infections: a key mediator in regulating
disease outcome. Curr. Opin. Immunol. 1995, 7, 485-496.
(63) Traub, S.; Kubasch, N.; Morath, S.; Kresse, M.; Hartung, T.; et
al. Structural requirements of synthetic muropeptides to syn-
ergize with lipopolysaccharide in cytokine induction. J. Biol.
Chem. 2003, 279, 8694-8700.
(64) Ando, K.; Moriyama, T.; Guidotti, L. G.; Wirth, S.; Schreiber, R.
D.; et al. Mechanisms of class I restricted immunopathology. A
transgenic mouse model of fulminant hepatitis. J. Exp. Med.
1993, 178, 1541-1554.
(65) Xiao, X. Y.; Li, R.; Zhuang, H.; Ewing, B.; Karunaratne, K.; Lillig,
J.; et al. Solid-phase combinatorial synthesis using MicroKan
reactors, Rf tagging, and directed sorting. Biotechnol. Bioeng.
2000, 71, 44-50.
(66) Liu, G.; Zhang, S. D.; Xia, S. Q.; Ding, Z. K. Solid-phase synthesis
of muramyl dipeptide (MDP) derivatives using a Multipin
method. Bioorg. Med. Chem. Lett. 2000, 10, 1361-1361.
(67) Schmittel, A.; Keilholz, U.; Scheibenbogen, C. Evaluation of the
interferon-γ ELISPOT-assay for quantification of peptide specific
T lymphocytes from peripheral blood. J. Immunol. Methods
1997, 210, 167-174.
(68) Kaplan, J. M.; Yu, Q.; Piraino, S. T.; Pennington, S. E.;
Shankara, S.; et al. Induction of anti-tumor immunity using
dendritic cells transduced with adenovirus vector-encoding
endogenous tumor-associated antigens. J. Immunol. 1999, 163,
699.
JM0493313